Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Study sponsor: Candel Therapeutics, Inc. · CADL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-11Actual
Enrollment · participants187Actual
Source updated2026-10-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.